Is Natural Capsules overvalued or undervalued?

Oct 07 2025 08:03 AM IST
share
Share Via
As of October 6, 2025, Natural Capsules is considered overvalued with a valuation grade of expensive, a PE ratio of -46.29, an EV to EBITDA of 18.72, and a one-year return of -21.97%, underperforming against the Sensex.
As of 6 October 2025, the valuation grade for Natural Capsules has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of -46.29, an EV to EBITDA of 18.72, and a ROCE of 3.81%.

In comparison to its peers, Sun Pharma has a PE ratio of 34.56 and an EV to EBITDA of 23.42, while Cipla is valued attractively with a PE ratio of 22.72 and an EV to EBITDA of 15.97. Notably, Natural Capsules has underperformed against the Sensex, with a one-year return of -21.97% compared to the Sensex's 0.12%, reinforcing the notion of its overvaluation.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News